Nothing Special   »   [go: up one dir, main page]

Borthwick, 2005 - Google Patents

Design of translactam HCMV protease inhibitors as potent antivirals

Borthwick, 2005

Document ID
1950896845246031333
Author
Borthwick A
Publication year
Publication venue
Medicinal research reviews

External Links

Snippet

Human cytomegalovirus (HCMV) is an important pathogen for which there is a significant unmet medical need. New HCMV antivirals, active against novel molecular targets, are undoubtedly needed as the currently available drugs ganciclovir, cidofovir, and foscarnet …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

Similar Documents

Publication Publication Date Title
Millies et al. Proline-based allosteric inhibitors of Zika and Dengue virus NS2B/NS3 proteases
WO2021226546A1 (en) Protease inhibitors for treatment or prevention of coronavirus disease
ES2346233T3 (en) SULFUR COMPOUNDS AS INHIBITORS OF SERINA PROTEASA NS3 OF THE VIRUS OF HEPATITIS C.
ES2328596T3 (en) PROLINES REPLACED AS INHIBITORS OF SERINA PROTEASA OF VIRUS NS3 OF HEPATITIS C.
WO2021205296A1 (en) Method of treating covid-19
US20240083885A1 (en) Compositions and methods for inhibiting m pro protease activity and for preventing and treating sars-cov-2 infection
US9808527B2 (en) Methods and compositions for treating HIV infections
Borthwick Design of translactam HCMV protease inhibitors as potent antivirals
Zhu et al. Viral proteases as targets for coronavirus disease 2019 drug development
Keller et al. Finding new medicines for flaviviral targets
Yu et al. Structure-based design of a dual-targeted covalent inhibitor against papain-like and main proteases of SARS-CoV-2
Leal et al. Discovery of novel dengue virus entry inhibitors via a structure-based approach
Tsuji et al. Structure–activity relationship studies of SARS-CoV-2 main protease inhibitors containing 4-fluorobenzothiazole-2-carbonyl moieties
US20250186374A1 (en) Allosteric inhibitors of the main protease of sars-cov-2
Skoreński et al. Anti-herpesvirus agents: a patent and literature review (2003 to present)
Jiang et al. Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate
Flury et al. Cathepsin-targeting SARS-CoV-2 inhibitors: design, synthesis, and biological activity
Breidenbach et al. Macrocyclic azapeptide nitriles: structure-based discovery of potent SARS-CoV-2 main protease inhibitors as antiviral drugs
Dou et al. Design, synthesis, and in vitro evaluation of potential West Nile virus protease inhibitors based on the 1-oxo-1, 2, 3, 4-tetrahydroisoquinoline and 1-oxo-1, 2-dihydroisoquinoline scaffolds
G Barros et al. Novel peptide mimetics based on N-protected amino acids derived from isomannide as potential inhibitors of NS3 serine protease of hepatitis c virus
Zhou et al. Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study
Benedetti et al. Synthesis and biological activity of potent HIV-1 protease inhibitors based on Phe-Pro dihydroxyethylene isosteres
US20240228460A1 (en) Protease inhibitors and methods of making same
Sole Burali et al. Broad-spectrum anti-flavivirus activity and chemistry of compounds containing sulfur and oxygen chalcogens
Huynh et al. Asymmetric imidazole-4, 5-dicarboxamide derivatives as SARS-CoV-2 main protease inhibitors: design, synthesis and biological evaluation